[Event Report] The First HGPI Dementia Policy Project Roundtable Discussion on “Establishing a Multi-Stakeholder Public-Private Partnership in the Field of Dementia – Driving Parallel Progress on an Inclusive Society and in R&D” (August 31, 2022)
date : 9/28/2022
Tags: Dementia
![[Event Report] The First HGPI Dementia Policy Project Roundtable Discussion on “Establishing a Multi-Stakeholder Public-Private Partnership in the Field of Dementia – Driving Parallel Progress on an Inclusive Society and in R&D” (August 31, 2022)](https://hgpi.org/en/wp-content/uploads/sites/2/d1f548405b0cfbda57b565bb2492b999.jpg)
On August 31, 2022, Health and Global Policy Institute (HGPI) held the first roundtable discussion for an initiative titled, “Establishing a Multi-Stakeholder Public-Private Partnership in the Field of Dementia – Driving Parallel Progress on an Inclusive Society and in R&D.” The meeting was held online and was not open to the public.
HGPI views dementia and all other aging-related issues as health policy issues at the global level and has made continuous efforts in its capacity as a non-profit, independent health policy think tank to advance policies in this area around the world. In particular, HGPI was early to call for all-of-government initiatives for addressing dementia and has issued multiple recommendations to that end. The fruits of these efforts can be seen in the National Framework for Promotion of Dementia Policies formulated in 2019.
However, establishing a Public Private Partnership (PPP) that enables industry, Government, academia, and civil society to collaborate in R&D in the field of dementia and to achieve a dementia-friendly society remains an issue. In other fields such as cancer, there have already been initiatives to advance R&D with active involvement from patient advocacy organizations in clinical trials. The field of dementia has also reached the point where we should establish a platform that enables a broad variety of stakeholders to collaborate on the creation of an inclusive society and to promote R&D.
After a preliminary survey of members from academia was conducted and issues were sorted, this roundtable discussion examined issues and next steps to be taken with three discussion points as themes:
Discussion point 1: Policy issues surrounding R&D and the direction to take moving forward
Discussion point 2: Challenges facing Patient and Public Involvement (PPI) in dementia research
Discussion point 3: Issues surrounding R&D programs
This roundtable was a significant opportunity for multi-stakeholders representing industry, Government, academia, and civil society to meet and exchange opinions on the future of R&D in a manner that surpassed each member’s position and field.
■ Roundtable discussion members (titles omitted; in Japanese syllabary order)
- Haruhiko Akiyama (Director of Clinical Research, Department of Clinical Research, Yokohama Municipal Stroke and Neurospine Center)
- Takeshi Ikeuchi (Professor, Center for Bioresource-based Researches, Brain Research Institute, Niigata University)
- Kenji Ishii (Team Leader, Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology)
- Takeshi Iwatsubo (Professor, Department of Basic Neuroscience, Department of Neurology, Graduate School of Medicine, The University of Tokyo; Director, Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital)
- Hidetaka Ota (Professor and Director, Advanced Research Center for Geriatric and Gerontology, Akita University (ARGG))
- Tomoo Ogawa (Director, Department of Clinical Research and Development, Japan-Asia, Alzheimer’s Disease and Brain Health, Eisai Co., Ltd.)
- Hideaki Katagiri (Medical Fellow and Lead Physician, Neuroscience & Pain, Medicine Development Unit Japan and Medical Affairs, Eli Lilly Japan K.K.)
- Naomi Sakurai (President, Cancer Solutions Co., Ltd.)
- Keisuke Suzuki (Director, Innovation Center for Translational Research, National Center for Geriatrics and Gerontology)
- Morio Suzuki (Representative Director, Alzheimer’s Association Japan (AAJ))
- Taro Semba (Director, Dementia Project Promotion Office, SOMPO Holdings, Inc.)
- Toshihisa Tanaka (Professor, Department of Neuromuscular Pathology, Mie University)
- Taisuke Tomita (Professor, Laboratory of Neuropathology & Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo)
- Jin Higashijima (Associate Professor, Graduate School of Global and Transdisciplinary Studies, Chiba University)
- Masaaki Hirai (Representative, Mahoroba Club)
Top Research & Recommendations Posts
- [Announcement] HGPI Joins Call for “Global Health and Medical Community Unite To Demand End Fossil Fuel Dependency at COP28” (November 1, 2023)
- [Research Paper] “Rethinking Japan’s Health System Sustainability Under the Planetary Health Framework” Published in Health Systems & Reform (November 21, 2023)
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Research Report] The Public Opinion Survey on Child-Rearing in Modern Japan (Final Report) (March 4, 2022)
- [Policy Recommendations] Furthering the Development of Precision Cancer Medicine —Proposals for Effective Policy Changes Based on Key Characteristics of Precision Medicine in Cancer Treatment— (September 20, 2022)
- [Activity Report] HGPI Submits Requests for the G7 Hiroshima Summit to the G7 Sous-Sherpa (December 23, 2022)
- [Announcement] HGPI Declares the Ministry of the Environment-led ‘Deco-Katsu Declaration’ and Participation in the ‘Deco-Katsu’ Supporters (October 16, 2023)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Urgent Recommendations] The Kidney Disease Control Promotion Project – Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration: Recommendations for Current Issues and Topics in Kidney Disease Control (May 11, 2022)
- [Case Study] Akari Shigemi “The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance” (AMR Alliance Japan, December 22, 2021)
Featured Posts
-
2023-10-31
[Registration Open] Online Public Symposium “Dementia Risk Reduction: How Society Should Face the Individualization of Risk” (December 12, 2023)
-
2023-11-27
[Registration Open] (Webinar) HGPI Cooperation with Lancet Countdown 2023 Japan Presentation “Climate Change as a Children’s Health Issue: The Latest Lancet Report Sounds the Alarm for Health Commitments” (December 14, 2023)
-
2023-11-28
[Event Report] The 1st Advisory Board Meeting for Patient and Public Involvement (PPI) Support Project “Necessary Steps for Promoting PPI in Policy Making” (October 3, 2023)
-
2023-11-29
[Policy Recommendations] Coming Together to Protect and Foster: Promoting Innovative and Sustainable Planetary Health in the Asia-Pacific Region to Build Resilient Health Systems (November 29, 2023)
-
2023-11-30
[Announcement] HGPI Endorsed “For the Health of People and Planet: Priorities for a Healthy COP28” (November 30, 2023)